INTRODUCTION
The symposium on aplastic anemia was held at the 8th meeting of the Japanese Society of Clinical Hematology in September 1965 and the author was given an opportunity to be a chairman of the symposium. Considering it to be the chairman's responsibility, the outline of the speeches and the comparative studies of the different results will be described and some comments also made from my own viewpoint in the present paper. INCIDENCE It has long been said that incidence of aplastic anemia in Japan is much higher than that in Europe and the United States. From my previous review1 of the literature, it was indicated in Europe and the United States that aplastic anemia was found only 3 cases a year on the average in the hospital where dis tinguished hematologist worked, whereas in Japan 5 to 6 cases a year on the average and that secondary aplastic anemia due to drugs was found more frequently than in Japan. In fact very few in-patients of aplastic anemia were able to be observed during my visiting trip at the various hospitals in Europe and the United, States (1957-58) . In the symposium, first of all , the incidence of aplastic anemia and leukemia for the last eleven years was studied with the cooperation of many hospitals. The results are shown in Fig. 1 , and Table 1 . As indicated in the chart, incidence of aplastic anemia is of about 44% of that of acute leukemia, 1.4 fold of chronic leukemia and approximately 33% of total number of leukemia and there is little difference in the ratio before and after 1960. Pediatric -patients are excluded in this study, therefore, actual figure is Table 1 Types of Aplastic Anemia reported from 51 Hospitals in Japan * Atypical aplastic anemia indicated cases having more than two of following items .
(1) More than 10%, of reticulocytes.
(2) More than 10% of monocytes.
No elevation of both serum iron and serum copper. (4) Splenomegaly.
supposed to be higher and continues to increase year after anotner, From this figure, the importance of the study of aplastic anemia should be emphasized and secondary aplastic anemia reveals approximately of 10%, although much less than
Europe and the United States, and pure red cell anemia is by no means few. In the symposium, Takaku defined the disease as the disorder in stem cell differentiation by citing Jandle's Table7. He indicated the following three points as clinical criteria: 1) pancytopenia, 2) hypoplasia of the bone marrow and 3) no responsiveness to specific treatment. Of these, hypoplasia is proved as a rule by bone marrow puncture, however, he called an attention of erroneous diagnosis without studying various parts of the bone marrow and findings of bone marrow could not always be used as a clinical index, since hypoplasia would include, in addition to absolute hypoplasia, relative one advocated by Moor and others-hematopoietic tissue can not be responsive despite of anemia. For deter mination of hematopoietic function, he indicated 1) investigation of the bone marrow of entire body at autopsy, 2) 59Fe turnover, 3) measurement of total reticulocytes, and 4) excretion of urobilinogen in feces.
According to the abovementioned criteria, anemia due to maturation disorder of the differentiated cell will not be included in aplastic anemia, therefore cases of refractory anemia reported by Bjorkman In common use of medical terms, "acute" and "chronic" immediately imply "short"
and "long" course. Accordingly the author considers it more proper to use "severe" and "mild" instead . To be more specific, as Umehara previously pro posed, degree of severity of the disease should be standardized using counting points. Some scholars, however, may have objections against Umehara's method of counting points. My co-workers and I have used "idiopathic," "secondary," "congenital"
and "special" types .
Furthermore, the standards described below had been used for the aid of clas sification. 
ETIOLOGY
There have been many theories as to the etiology of "idiopathic" aplastic anemia. In my previous paper15 these theories were once throughly studied with our clinical and laboratory findings. In the symposium, Arimori also made a comment using the results of the experiment conducted by his group. He pointed out the disorder in amino acid metabolism, particularly in amino acid formation of mitochondria, and also in biosynthesis of fatty acid. Electronmicroscopic study indicated, he continued, that erythrocytoblastic mitochondria was more polymorphic than usual. Some scholars considered, however, that it may be produced artificially. Whether these changes are the cause or the result of the disease remains as a problem for future studies, he assumed that virus or immune mechanism would be responsible for mitochondria disorder. Kawakita con sidered the significance of the spleen, and also emphasized the racial difference in the incidence of aplastic anemia which would be an important subject of study. Uzuka explained an assumption that antigen antibody reaction would be involved in the hypoplasia of the marrow, and that disturbance of cell maturation would be due to the lack of unknown factor(s). Considering of bone marrow capillaropathy due to allergy or virus, Ito proposed a new theory that disorder would by no means of erythron itself nor bone marrow cell. Umehara emphasized this theory in his speech. It is expected that detailed report supporting this theory will be published. On this subject, my report18 was previously made in 1959. In the present study, however, poor prognosis of significant difference was observed in those with body temperature higher than 37.5•Ž and bleeding time longer than 20 minutes. No noticeable difference of prognosis was indicated in erythrocytes, leukocytes, granulocytes, blood platelets, reticulocytes (absolute number), eryth rocyte sedimentation rate and serum iron and copper. These results slightly differed from those in the previous report. The reason may have been that the cases treated with adrenocortical hormone were included in this study. Some groups consider that splenectomy is effective in some cases but efficacy is not so highly evaluated because of the standard of determining effectiveness. For instance, in a case of delayed improvement it is hard to determine whether or not splenectomy is responsible. It may be due to the adequacy of pre or post-splenectomic medicine or treatment. Particularly nowadays when adreno cortical hormone proves to be as effective as splenectomy, some even consider that splenectomy is not necessarily required. Kawakita also stated that he would perform splenectomy only after adrenocortical hormone turned out to be ineffec tive. Ito stressed the reduction of mortality and the increase of longer survival, indicating 44.2% of mortality of 77 cases 5 years after administration of adrenocortical steroid and 50.0% of untreated control cases within 3 months. Effectiveness against pyrexia was of 64.4%, 70.6% of cases could extend interval of blood transfusion and against hemorrhage of 67.5%. Dose was considerably large at the early stage of the treatment in hospital when hemorrhage and pyrexia were accompanied, however, maintenance dose was reduced to 15-20 mg in Prednisolone. Miura reported improvement in ferrokinetics was not obtained immediately after administration of Prednisolone but later in several months. This finding was consistent with my previous assumption based on the hemato chemical findings of aplastic anemia that adrenccorticai steroid had no direct action of accelerating bone marroow activity.'8 Miura furthermore admitted the fact that survival of longer than one year was significantly more in number in the drug-administered group, however, he avoided making definite statement on the immediate effect of the drug. The dose in his study was Prednisolone 15-30 mg and ACTH 10-20 unit. Iwasaki expressed the preference of concomitant use of adrenocortical steroid and ACTH to use of the former alone, indicating that one died out of 4 patients to whom Prednisolone alone was administered while 8 in 22 patients of concomitant administration. He also added that autopsy of the cases of concomitant use revealed no atrophy of the adrenal gland. Initial dose in his report was 20-30 mg of Prednisolone, which was reduced to the mainte nance dose of 10 mg with temporary increase up to 60-100 mg at the time of pyrexia, and ACTH 10 unit per day. 
